Related Experiment Video
Updated: Jan 29, 2026

Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens
Published on: January 21, 2019
Current Coverage of the mTOR Pathway by Next-Generation Sequencing Oncology Panels
Rita Seeboeck1,2, Victoria Sarne3, Johannes Haybaeck4,5,6,7
1Clinical Institute of Pathology, University Hospital St. Poelten, Karl Landsteiner University of Health Sciences, 3100 St. Pölten, Austria. rita.seeboeck@stpoelten.lknoe.at.
Abstract:
The mTOR pathway is in the process of establishing itself as a key access-point of novel oncological drugs and targeted therapies. This is also reflected by the growing number of mTOR pathway genes included in commercially available next-generation sequencing (NGS) oncology panels. This review summarizes the portfolio of medium sized diagnostic, as well as research destined NGS panels and their coverage of the mTOR pathway, including 16 DNA-based panels and the current gene list of Foundation One as a major reference entity. In addition, we give an overview of interesting, mTOR-associated somatic mutations that are not yet incorporated. Especially eukaryotic translation initiation factors (eIFs), a group of mTOR downstream proteins, are on the rise as far as diagnostics and drug targeting in precision medicine are concerned. This review aims to raise awareness for the true coverage of NGS panels, which should be valuable in selecting the ideal platform for diagnostics and research.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
Next-generation Sequencing
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
Wood Panel Products
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...
Electrical Current

